The National Institute for General Medical Sciences has awarded BellBrook Labs a one million dollar SBIR Phase II grant for the continued development, optimization and validation of a fluorescent HTS assay for human sulfotransferases. Sulfotransferase enzymes play an important role in the metabolism of drugs. The concerns of drug metabolism, such as drug/drug interactions and the production of toxic metabolites, are the focus of pharmaceutical efforts and play a key role in the extremely high failure rate of clinical trials.
The most promising approach for effectively managing the success of clinical trials is the implementation of strategies that predict drug metabolism. A high throughput screening assay for characterizing sulfotransferases is one such effective approach. BellBrook Lab’s Transcreener™ Sulfotransferase Assay will enable a systematic approach toward characterizing and profiling drug metabolism before clinical trials.
BellBrook Labs develops high throughput screening tools that accelerate the discovery of more effective therapies. The proprietary technology, Transcreener™ HTS assay platform is a universal, homogenous assay that uses a single set of detection reagents across a family of enzymes, thus enabling the seamless incorporation of hundreds of new drug targets into HTS format. The benefits are clear: lowered development costs, accelerated discovery, standardized methodology, and eliminated delays. The Transcreener™ HTS assay platform will change the metrics of HTS
Biology at Work